Scientists have discovered two related mediators of fibrosis and potential therapeutic targets: transcription factor, KLF10 and the cytokine, IL-9 for the treatment of hypertension-associated fibrosis.
Fibromyalgia associated with hypertension
Although recent data have suggested that the thickening is due to the activation of T cells, the guardians of our immune system, the underlying mechanisms remain largely unknown.
‘Elevated blood pressure can cause a condition known as perivascular fibrosis, in which the outer wall of a blood vessel thickens due to a build-up of connective tissue.’
To further study how fibrosis develops, the Brigham researchers analyzed mononuclear immune cells in peripheral blood from patients with high blood pressure.
When the researchers injected mice with IL-9-neutralizing antibodies, they observed a reversal of fibrosis and prevention of organ dysfunction, building a stronger case for targeting spend this road.
Senior author Mark W. Feinberg, MD, of the Division of Cardiovascular Medicine, said: “Because hypertension contributes to a significant number of cardiovascular-related deaths globally, we I wanted to look at the depth of perivascular fibrosis for potential drug targets.” “We are eager to continue investigating KLF10-IL-9 signaling to hopefully create effective treatments for vascular diseases.”